safinamide

Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098μM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8μM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy.

Safinamide mesylate (EMD 1195686 mesylate) , a mesylate salt of Safinamide, can reversibly and specifically inhibit MAO-B (IC50: 98 nM), has 5918-fold selectivity against MAO-A.

Safinamide acid, a potential impurity in commercial safinamide preparations and a degradation product of safinamide under thermal and oxidative stress, is encountered in the pharmaceutical formulation process.

MAO-B-IN-6 is a selective, potent, orally active MAO-B inhibitor (IC50: 0.019 μM) and demonstrates superior efficacy to Safinamide both in vitro and in vivo.

NW-1689 is a process-related impurity of safinamide mesilate (SAFM), which is a medication used in the treatment of Parkinson's disease (PD). SAFM acts as a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium and N-type calcium channels. These actions assist in reducing dopamine breakdown and suppressing glutamate release. NW-1689 shares structural similarities with SAFM and exhibits comparable pharmacological effects, making it applicable in Parkinson's disease research.